Category Archives: Regenerative Medicine

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical Limited (Company) (ASX:AVH) (NASDAQ:RCEL) today announced that management will present virtually at the upcoming Jefferies Virtual Health Conference on Wednesday, June 3, 2020 at 4:30 p.m. EDT.

Authorised for release by the Chief Financial Officer of AVITA Medical Limited.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION), an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

Read more:
AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference - Business Wire

MarketsandResearch.biz has released a new research report titled Global Regenerative Medicine Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 to its database which presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis, and key drivers. The report encompasses all the prime factors, making this report extremely useful to all the entrants and potential investors in the global Regenerative Medicine market. The data simplifies this study using a series of channels, including data ranging from rudimentary data to meticulously drawn estimates. Key drivers, as well as challenges of the market, are discussed in the report. The report provides an in-depth analysis of the market with current and future trends.

The report further talks about the definition, types, applications, and major players of the Regenerative Medicine market in detail. The report offers thorough knowledge about the opportunities in business, market status& forecast, the possibility of generating revenue, regional market by different end-users as well as types and future forecasts of upcoming years. The report looks at market status (2015-2020), competitive scenario, advantages and disadvantages of different products and different market players, industry development trends and insights (2020-2026), and regional dominant participants.

NOTE: Our final report will be revised to address COVID-19 effects on the specific market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/44907

Below mentioned is the list of few companies engaged in the market: ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter,

On the basis of product types of market: Mono Avalanche Airbags, Dual Avalanche Airbags

The study explores the key applications/end-users of the market: Skiing, Climbing, Hiking, Others

Furthermore, the report includes a deep compilation of the respective industry and a detailed overview of its segmentation. The report offers a fundamental outlook of the global Regenerative Medicine markets present status and size in terms of volume and value. The essential data about the vital geographical regions and primitive players has been summarized in the report. The market has been broken down into various segments, regions, end-uses, and players to provide a clear picture of the present market situation. Segmentation of the market highlights the growth prospects and trends impacting these segments.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/44907/global-regenerative-medicine-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2026

The Geographical Landscape of The Market:

The research offers an analysis of the geographical landscape of the global Regenerative Medicine market, which is divided into regions such as North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). It includes data about several parameters related to the regional contribution. The study provides information regarding the sales generated through each region and the registered market share. Information related to the growth rate during the forecast period is included in the report. According to the report, the industry is projected to generate significant revenue during the forecast period.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Read more:
Global Regenerative Medicine Market Research Report With COVID-19 Update - Cole of Duty

A clinical trial showed the ability of a stem cell-based topical solution to regrow hair in people with male/female pattern baldness.

The results of a clinical trial released today (May 18, 2020) in STEM CELLS Translational Medicinedemonstrate how a topical solution made up of stem cells leads to the regrowth of hair for people with a common type of baldness.

Androgenetic alopecia (AGA) commonly known as male-pattern baldness (female-pattern baldness in women) is a condition caused by genetic, hormonal and environmental factors. It affects an estimated 50 percent of all men and almost as many women older than 50. While it is not a life-threatening condition, AGA can lower a persons self-esteem and psychological well-being. There are a few FDA-approved medications to treat hair loss, but the most effective can have side effects such as loss of libido and erectile dysfunction. Therefore, the search continues for a safer, effective treatment.

Adipose tissue-derived stem cells (ADSCs) secrete several growth hormones that help cells develop and proliferate. According to laboratory and experimental studies, growth factors such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF) and platelet-derived growth factor (PDGF) increase the size of the hair follicle during hair development.

A more enriched adipose-derived stem cells-constituent extract (ADSC-CE) with stem cell proteins is obtained by disruption of the ADSC membrane using a low frequency of ultrasound wave. Credit: AlphaMed Press

Recent studies have shown that ADSCs promote hair growth in both men and women with alopecia. However, no randomized, placebo-controlled trial in humans has explored the effects and safety of adipose-derived stem cell constituent extract (ADSC-CE) in AGA. We aimed to assess the efficacy and tolerability of ADSC-CE in middle-aged patients with AGA in our study, hypothesizing that it is an effective and safe treatment agent, said Sang Yeoup Lee, M.D., Ph.D., of the Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital in South Korea. He led the group of researchers, which also included colleagues from Pusan National University School of Medicine, Pusan National University Yangsan Hospital and T-Stem Co., Ltd.

The team recruited 38 patients (29 men and nine women) with AGA and assigned half to an intervention group that received the ADSC-CE topical solution and half as a control group that received a placebo. Twice daily, each patient applied the ADSC-CE topical solution or placebo to their scalp using their fingers.

At the end of 16 weeks, the group that received the ADSC-CEs had a significant increase in both hair count and follicle diameter, reported the studys senior author, Young Jin Tak, M.D., Ph.D.

Dr. Lee added, Our findings suggest that the application of the ADSC-CE topical solution has enormous potential as an alternative therapeutic strategy for hair regrowth in patients with AGA, by increasing both hair density and thickness while maintaining adequate treatment safety. The next step should be to conduct similar studies with large and diverse populations in order to confirm the beneficial effects of ADSC-CE on hair growth and elucidate the mechanisms responsible for the action of ADSC-CE in humans.

For the millions of people who suffer from male-pattern baldness, this small clinical trial offers hope of a future treatment for hair regrowth, said Anthony Atala, M.D., Editor-in-Chief ofSTEM CELLS Translational Medicineand director of the Wake Forest Institute for Regenerative Medicine. The topical solution created from proteins secreted by stem cells found in fat tissue proves to be both safe and effective. We look forward to further findings that support this work.

###

Reference: A Randomized, Double-blind, Vehicle-Controlled Clinical Study of Hair Regeneration Using Adipose-Derived Stem Cell Constituent Extract in Androgenetic Alopecia by Young Jin Tak, Sang Yeoup Lee, A Ra Cho and Young Sil Kim, 18 May 2020, STEM CELLS Translational Medicine.DOI: 10.1002/sctm.19-0410

AboutSTEM CELLS Translational Medicine:STEM CELLS Translational Medicine(SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals:STEM CELLS, celebrating its 38th year, is the worlds first journal devoted to this fast paced field of research.The Oncologist, also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Go here to read the rest:
New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair - SciTechDaily

PHOENIX--(BUSINESS WIRE)--BioLab Sciences, a regenerative biotechnology company, today announced a partnership with Red One Medical that will help veterans and active military members access breakthrough wound healing and regenerative medicine.

Red One Medical is private sector innovation partner of Department of Veterans Affairs (VA) and Department of Defense (DoD) hospitals. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), it provides advanced medical and pharmaceutical technologies that improve patient care for America's military veterans. BioLab Sciences is working with Red One Medical to distribute regenerative medicine products and MyOwn Skin, a novel biotechnology that can accelerate the healing of severe burns, chronic wounds, diabetic foot ulcers, and other difficult-to-heal wounds.

Nearly one in four veterans has diabetes, and as such, the need for an innovative wound care solution is critical to treat non-healing diabetic ulcersthe leading cause of lower-limb amputations in non-combat veterans.

Were constantly on the lookout for innovative products to speed wound healing in veteran and military hospitals," said Red One Medical CEO and Founder Charles Pollak. "We want our veterans to receive top quality care, and MyOwn Skin takes wound care to the next level by leveraging a patient's own skin to quickly grow skin grafts in a new, non-invasive way."

MyOwn Skin leverages a very small sample of a patient's skin and blood taken through a non-surgical procedure to reproduce three, 100cm2 skin grafts within a week. MyOwn Skin eliminates the need for traditional skin grafts which require surgical procedures to remove large areas of healthy skin from other parts of a patients body, often resulting in additional wounds requiring care and healing time.

We are on a mission to help patients and providers access regenerative medicine products that help the body achieve optimal performance, said BioLab Sciences President and CEO Bob Maguire. As the VAs private sector innovation partner, Red One Medical is in a unique position to help advance the delivery of care to our nations veteran and military patients. This partnership is one step forward in that direction.

Along with MyOwn Skin, which is now one of the most advanced products in Red One Medical's wound care portfolio, the company will also distribute BioLab Sciences amniotic allograft membrane, amniotic liquid allograft and other regenerative products that promote healing for wound, orthopedic, respiratory and ophthalmic care. The products will be available to the DoD and VA health system, which includes more than 9 million veterans at approximately 1,700 facilities.

About BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin, a remarkable biotechnology that leverages a small sample of a patient's own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week. Learn more at http://www.biolabsciences.net/.

About Red One Medical

Red One Medical is a private sector innovation partner of Department of Veterans Affairs (VA) medical centers and Department of Defense (DoD) hospitals. Red One Medical identifies and delivers advanced medical and pharmaceutical technologies that transform care for Americas military veterans. Located in Savannah, GA, Red One Medical is a CVE-certified Service Disabled Veteran Owned Business (SDVOSB) and SBA-certified Historically Underutilized Business Zone (HUBZone) company. It donates a portion of profits to charities that support veterans, military families and their communities.

Read this article:
BioLab Sciences Partners with Red One Medical to Provide Transformative Wound Healing Products to Veterans and Active Military - Business Wire

MIAMI, May 21, 2020 /PRNewswire-PRWeb/ --Having the cushion of an already established worldwide network and 10 years of experience of GSCG, VITA NOVAS has already gained ground with the inherited reputation of quality, innovation, and professionalism. The VITA NOVAS' program delivers micro-nutrients , vitamins and stimulating biological products intravenously, guaranteeing an effective way for the ingredients to become immediately available to the cells. This greatly decreases the time it takes for the medication or supplements to take effect. Patient-centered carved out packages The Shield, the Fighter, and the Lightening are delivered on-demand to homes, offices, or hotels administered by certified healthcare professionals.

Believing on the precept of Prevent-Protect-Thrive, VITA NOVAS aspires to set standards in the industry, and committed to ensure in-home, and personalized patient service; keeping them away from hospitals and emergencies. VITA NOVAS offers infusion packages, mixed with essential fluids, electrolytes, vitamins, and antioxidants as a powerful cocktail to stimulate the immune system and help bolster it to assist in fighting infections and diseases. In-line with the evolved life pattern of social distancing, the process of treatment at VITA NOVAS is as simple as:

Select Your Service Area

Schedule a video consultation with our local doctors to discuss your possible treatment plan

Receive the treatment at home

"We have combined elements of Tele-health with Regenerative therapy, IV wellness infusions, and a direct-to-consumer model intending to serve at the patient's' place of residence, due to convenience and social distancing practices," explains Benito Novas , CEO of VITA NOVAS.

The secret behind the VITA NOVAS program is the provision of assistance and prime incentives to medical professionals. Once a physician joins the network, the company provides training and support that they will need in order to set-up run, and market their practices. They enjoy geography and specialization exclusively as well as a strong network of patients referrals, increased revenues, and conduct consultations from home.

Global Stem Cells Group, with golden track record and experience of a decade, is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2010 by Benito Novas, the company combines dedicated researchers, physicians, patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading-edge Regenerative Medicine treatments. Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology, while adhering to the highest medical standards.

VITA NOVAS can help, to find your service area, please visit: http://www.vitanovas.net To know more about the company, visit http://www.stemcellsgroup.com

SOURCE Global Stem Cells Group

Go here to read the rest:
Global Stem Cells Group Announces the Launch of its New Division VITA NOVAS - Benzinga

The recently published market study by MRRSE highlights the current trends that are expected to influence the dynamics of the Regenerative Medicine market in the upcoming years. The report introspects the supply chain, cost structure, and recent developments pertaining to the Regenerative Medicine market in the report and the impact of the COVID-19 on these facets of the market. Further, the micro and macro-economic factors that are likely to impact the growth of the Regenerative Medicine market are thoroughly studied in the presented market study.

According to the report, the Regenerative Medicine market is expected to grow at a CAGR of ~XX% during the forecast period, 20XX-20XX and attain a value of ~US$ XX by the end of 20XX. The report is a valuable source of information for investors, stakeholders, established and current market players who are vying to improve their footprint in the current Regenerative Medicine market landscape amidst the global pandemic.

Request Sample Report @https://www.mrrse.com/sample/6729?source=atm

Reasons to Trust Our Business Insights

Critical Data in the Regenerative Medicine Market Report

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/6729?source=atm

Regional Assessment

The regional assessment chapter in the report offers an out and out understanding of the potential growth of the Regenerative Medicine market across various geographies such as:

Application Assessment

The presented study ponders over the numerous applications of the Regenerative Medicine and offers a fair assessment of the supply-demand ratio of each application including:

segmented as follows:

Regenerative Medicine (Bone and Joint) Market, by Technology

Regenerative Medicine (Bone and Joint) Market, by Application

Regenerative Medicine (Bone and Joint) Market, by Geography

View original post here:
Impact of COVID-19 Outbreak on Regenerative Medicine Market with Global Innovations, Competitive Analysis, New Business Developments and Top Companies...

CHICAGO,May 20, 2020/PRNewswire/ Brian J. Cole, M.D., M.B.A, sports medicine surgeon and Managing Partner atMidwest Orthopaedics atRush,has been named President of theArthroscopy Association ofNorth America(AANA) for the 2020-2021 term. His new role is effective immediately.

I am truly honored to serve in this capacity for the AANA, explains Dr. Cole, who also serves as Associate Chairman and Professor in the Department of Orthopedics, Director of the Cartilage Restoration Center, and head of the Orthopedic Masters Training Program atRush UniversityMedical Center. Im grateful to have been selected by my peers who are some of the most talented orthopedic surgeons in the country.

A primary issue of focus for Dr. Cole and the AANA Board of Directors will be to encourage the development of additional research support, adapting educational initiatives to the current environment, advocacy, and providing practice management services for its nearly 6,000 members.

Dr. Cole also serves as the Chairman, Department of Surgery at Rush Oak Park Hospital; Head Team Physician for the Chicago Bulls; and Team Physician for the Chicago White Sox. He is the co-host of Sports Medicine Weekly on670AM The ScoreinChicagoand the Physician Director of the annualChicago Sports Summit.

He lectures nationally and internationally and holds several leadership positions in prominent sports medicine societies.Through his basic science and clinical research, he has developed several innovative techniques for the treatment of shoulder, elbow and knee conditions. He haspublished more than 1,000 articles and 10 widely read textbooks in orthopedicsand regenerative medicine.

Dr. Cole is frequently chosen as one of theBest Doctors in Americasince 2004 and as a Top Doctor in theChicagometro area since 2003. He was featured on thecover ofChicago Magazineas ChicagosTop Doctor and has been selected asNBA Team Physician of the Year.Orthopedics This Weeknamed Dr. Cole as one of the top 20 sports medicine, knee and shoulder specialists repeatedly over the last five years as selected by his peers.

SOURCE Midwest Orthopaedics atRush

http://www.rushortho.com

The rest is here:
Dr. Brian J. Cole Named President of the Arthroscopy Association of North America - OrthoSpineNews

This photo provided by the National Center for Child Health and Development shows liver cells produced from embryonic stem cells.This photo provided by the National Center for Child Health and Development shows human embryonic stem cells.

The National Center for Child Health and Development in Tokyo announced it has successfully conducted a clinical trial to transplant liver cells created from human embryonic stem cells into a baby with a serious liver condition.

It is the first clinical trial in Japan to use human embryonic stem cells, and is also believed to be the first case in the world of liver cells produced from embryonic stem cells being transplanted into a person.

The baby that received the transplant had hyperammonemia, a condition in which an abnormality in the natural urea cycle prevents toxic ammonia from being broken down in the liver. The abnormality is said to be prevalent in between one in 8,000 and one in 44,000 people.

In serious cases a liver transplant is required to treat it, but newborns have a high risk of experiencing major side effects. As a result, transplants cannot be conducted safely until several months after birth, when the baby weighs 6 kilograms or more.

In Europe and North America, doctors have utilized translational medicine, in which normally functioning liver cells are transplanted into newborns, to keep the liver functioning until an organ transplant can be carried out. In Japan, the National Center for Child Health and Development has previously transplanted liver cells from living donors into newborns with the condition soon after birth, but it has had difficulty in steadily securing liver cells.

Because of this, the center drew up plans to create liver cells from embryonic stem cells and transplant them. Over a period of two days in October 2019, it injected about 190 million liver cells into blood vessels in the umbilical cord of a 6-day-old newborn with hyperammonemia. The ammonia concentration in the infant's blood then stopped rising, enabling researchers to confirm that the liver cells had reached the newborn's liver, and the baby was temporarily discharged from the hospital.

Five months later, when the baby weighed 7 kilograms, a living donor liver transplant was carried out with the baby's father serving as the donor. The baby was again able to be discharged from the hospital in late April.

The center has received approval from the national government to use liver cells derived from embryonic stem cells in regenerative medicine, and plans to transplant them into several people subject to clinical trials in the future.

Center official Mureo Kasahara of the national center's organ transplant center commented, "It was often the case that babies with this condition died from seizures or suffered brain damage before the liver transplant could take place. The latest case is hugely significant in that we have proved the effectiveness of the method."

(Japanese original by Ayumu Iwasaki, Science & Environment News Department)

More here:
1st transplant using liver cells from embryonic stem cells conducted on baby in Japan - The Mainichi

The results of a new clinical trial published in the journal STEM CELLS Translational Medicine demonstrate how a topical solution made up of stem cells leads to the regrowth of hair for people with a common type of baldness.1

Unfortunately, there are only a few FDA-approved medications to treat hair loss, and these carry a myriad of associated side effects including a negative impact on sexual functioning. There is therefore a pertinent need to develop anti-hair loss treatments that lack such side effects.

Emerging research has demonstrated the potential application of stem cells, particularly adipose tissue-derived stem cells (ADSCs), in this space. ADSCs are a type of mesenchymal stem cell that secrete several growth hormones that facilitate cell development and proliferation.

As previous research has demonstrated that growth factors such as hepatocyte growth factor, vascular endothelial growth factor, insulin-like growth factor and platelet-derived growth factor increase the size of hair follicles during hair development, scientists have explored whether ADSCs can promote hair growth in men and women with alopecia.2,3 The results of such research have been positive, however, a randomized, placebo-controlled trial of such a therapeutic approach in AGA did not exist until now.

"Recent studies have shown that ADSCs promote hair growth in both men and women with alopecia. However, no randomized, placebo-controlled trial in humans has explored the effects and safety of adipose-derived stem cell constituent extract (ADSC-CE) in AGA," says Sang Yeoup Lee, M.D., Ph.D., of the Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital. "We aimed to assess the efficacy and tolerability of ADSC-CE in middle-aged patients with AGA in our study, hypothesizing that it is an effective and safe treatment agent."

Participants were instructed to apply 2mL of solution to the area in which they experienced hair loss, twice every day for a total of 16 weeks, massaging the solution into their scalp using their fingers. Each subjected visited the research center four times in total throughout the study, and were requested to keep a diary to record when they were using the solution.

To measure whether the solution was significantly impacting hair growth, the scientists measured changes in total hair number and hair thickness as confirmed by close contract photographs using a standardized technique. This was the primary efficacy variable. Photographs were taken at baseline, eight weeks and 16 weeks after using the product. At baseline, participants received a dot tattoo over their scalp to ensure that the photographs were taken at the same spot at each follow up. The secondary efficacy variables of the study included analysis of global photographs of the participants' scalps by an investigator, and self-evaluation of hair growth by the participants.

Whilst these results are promising, the authors note several limitations to the study. When assessing the secondary efficacy outcomes, the researchers found that the improvement score provided by the investigator was higher in the intervention group than the control, but this was not a significant increase. Additionally, the evaluation provided by the subject was lower in the intervention group. The scientists suggest that a contributing factor here could be the study duration, positing the idea that the length of time in which the participants were involved in the trial may not have been sufficient for them to notice a visual improvement. Furthermore, the self-report assessment could have been limited in validity as subjects may have been impacted by their own expectations towards the intervention. A solution to consider going forward could be to ask participants about their expectations regarding the magnitude of improvement at baseline.

Lee adds, "Our findings suggest that the application of the ADSC-CE topical solution has enormous potential as an alternative therapeutic strategy for hair regrowth in patients with AGA, by increasing both hair density and thickness while maintaining adequate treatment safety. The next step should be to conduct similar studies with large and diverse populations in order to confirm the beneficial effects of ADSC-CE on hair growth and elucidate the mechanisms responsible for the action of ADSC-CE in humans."

"For the millions of people who suffer from male-pattern baldness, this small clinical trial offers hope of a future treatment for hair regrowth," says Anthony Atala, M.D., Editor-in-Chief ofSTEM CELLS Translational Medicineand director of the Wake Forest Institute for Regenerative Medicine. "The topical solution created from proteins secreted by stem cells found in fat tissue proves to be both safe and effective. We look forward to further findings that support this work."

References:

1. Tak, Lee, Cho and Kim. (2020). A randomized, doubleblind, vehiclecontrolled clinical study of hair regeneration using adiposederived stem cell constituent extract in androgenetic alopecia. Stem Cells Translational Medicine. DOI: https://doi.org/10.1002/sctm.19-0410.

2. Ramdasi S, Tiwari SK. (2016). Growth factors and cytokines secreted in conditioned media by mesenchymal stem cells-promising possible therapeutic approach for hair regeneration. J Stem Cells. https://www.ncbi.nlm.nih.gov/pubmed/28296872.

3. Lee et al. (2001). Hepatocyte growth factor (HGF) activator expressed in hair follicles is involved in in vitro HGF-dependent hair follicle elongation. J Dermatol Sci. 25:156-163.

View original post here:
Clinical Trial Shows Topical Stem Cell Treatment Leads to Hair Regrowth in Common Type of Baldness - Technology Networks

DNA may not be lifes instruction book, but just a jumbled list of ingredients.

University of Maryland researcher develops potentially revolutionary framework for heredity and evolution in which inheritable information is stored outside the genome.

The common view of heredity is that all information passed down from one generation to the next is stored in an organisms DNA. But Antony Jose, associate professor of cell biology and molecular genetics at the University of Maryland, disagrees.

In two new papers, Jose argues that DNA is just the ingredient list, not the set of instructions used to build and maintain a living organism. The instructions, he says, are much more complicated, and theyre stored in the molecules that regulate a cells DNA and other functioning systems.

Jose outlined a new theoretical framework for heredity, which was developed through 20 years of research on genetics and epigenetics, in peer-reviewed papers in the Journal of the Royal Society Interface and the journal BioEssays. Both papers were published on April 22, 2020.

Joses argument suggests that scientists may be overlooking important avenues for studying and treating hereditary diseases, and current beliefs about evolution may be overly focused on the role of the genome, which contains all of an organisms DNA.

DNA cannot be seen as the blueprint for life, Jose said. It is at best an overlapping and potentially scrambled list of ingredients that is used differently by different cells at different times.

For example, the gene for eye color exists in every cell of the body, but the process that produces the protein for eye color only occurs during a specific stage of development and only in the cells that constitute the colored portion of the eyes. That information is not stored in the DNA.

In addition, scientists are unable to determine the complex shape of an organ such as an eye, or that a creature will have eyes at all, by reading the creatures DNA. These fundamental aspects of anatomy are dictated by something outside of the DNA.

Jose argues that these aspects of development, which enable a fertilized egg to grow from a single cell into a complex organism, must be seen as an integral part of heredity. Joses new framework recasts heredity as a complex, networked information system in which all the regulatory molecules that help the cell to function can constitute a store of hereditary information.

Michael Levin, a professor of biology and director of the Tufts Center for Regenerative and Developmental Biology and the Allen Discovery Center at Tufts University, believes Joses approach could help answer many questions not addressed by the current genome-centric view of biology. Levin was not involved with either of the published papers.

Understanding the transmission, storage and encoding of biological information is a critical goal, not only for basic science but also for transformative advances in regenerative medicine, Levin said. In these two papers, Antony Jose masterfully applies a computer science approach to provide an overview and a quantitative analysis of possible molecular dynamics that could serve as a medium for heritable information.

Jose proposes that instructions not coded in the DNA are contained in the arrangement of the molecules within cells and their interactions with one another. This arrangement of molecules is preserved and passed down from one generation to the next.

In his papers, Joses framework recasts inheritance as the combined effects of three components: entities, sensors and properties.

Entities include the genome and all the other molecules within a cell that are needed to build an organism. Entities can change over time, but they are recreated with their original structure, arrangement and interactions at the start of each generation.

That aspect of heredity, that the arrangement of molecules is similar across generations, is deeply underappreciated, and it leads to all sorts of misunderstandings of how heredity works, Jose said.

Sensors are specific entities that interact with and respond to other entities or to their environment. Sensors respond to certain properties, such as the arrangement of a molecule, its concentration in the cell or its proximity to another molecule.

Together, entities, sensors and properties enable a living organism to sense or know things about itself and its environment. Some of this knowledge is used along with the genome in every generation to build an organism.

This framework is built on years of experimental research in many labs, including ours, on epigenetics and multi-generational gene silencing combined with our growing interest in theoretical biology, Jose said. Given how two people who contract the same disease do not necessarily show the same symptoms, we really need to understand all the places where two people can be differentnot just their genomes.

The folly of maintaining a genome-centric view of heredity, according to Jose, is that scientists may be missing opportunities to combat heritable diseases and to understand the secrets of evolution.

In medicine, for instance, research into why hereditary diseases affect individuals differently focuses on genetic differences and on chemical or physical differences in entities. But this new framework suggests researchers should be looking for non-genetic differences in the cells of individuals with hereditary diseases, such as the arrangement of molecules and their interactions. Scientists dont currently have methods to measure some of these things, so this work points to potentially important new avenues for research.

In evolution, Joses framework suggests that organisms could evolve through changes in the arrangement of molecules without changes in their DNA sequence. And in conservation science, this work suggests that attempts to preserve endangered species through DNA banks alone are missing critical information stored in non-DNA molecules.

Jose acknowledged that there will be much debate about these ideas, and experiments are needed to test his hypotheses. But, he said, preliminary feedback from scientists like Levin and other colleagues has been positive.

Antony Joses generalization of memory and encoding via the entity-sensor-property framework sheds novel insights into evolution and biological complexity and suggests important revisions to existing paradigms in genetics, epigenetics and development, Levin said.

###

References:

A framework for parsing heritable information by Antony M. Jose, 22 April 2020, Journal of the Royal Society Interface.DOI: 10.1098/rsif.2020.0154

Heritable Epigenetic Changes Alter Transgenerational Waveforms Maintained by Cycling Stores of Information by Antony M. Jose, 22 April 2020, BioEssays.DOI: 10.1002/bies.201900254

Research in Antony Joses laboratory is supported by the National Institutes of Health (Award Nos. R01GM111457 and R01GM124356). The content of this article does not necessarily reflect the view of this organization.

Read more from the original source:
DNA May Not Be the Blueprint for Life Just a Scrambled List of Ingredients - SciTechDaily